ProCE Banner Events

PEMAZYRE: The First FDA-Approved Treatment for Adults With Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma With an FGFR2 Fusion or Other Rearrangement as Detected by an FDA-Approved Test

Pemazyre Key Learning Objectives:

  • Describe the PEMAZYRE indication
  • Discuss the role of molecular profiling in patient selection
  • Review the mechanism of action and indication for PEMAZYRE
  • Learn about the FIGHT-202 clinical study design, including patient characteristics
  • Review efficacy and safety results for FIGHT-202, including overall response rate and duration of response, and the safety profile of PEMAZYRE
  • Review the FIGHT-202 4-year follow-up analysis long-term data
  • Discuss PEMAZYRE dosing, including situations requiring dose modifications
  • Learn about how IncyteCARES can assist patients and the care team
Time and location

Wednesday, May 07, 2025

12:15 PM - 12:45 PM Eastern Time (ET)

Virtual

Acknowledgement

Sponsored By

Incyte

Additional Information

Prescribing Information